SMMT Summit Therapeutics Inc. - 8-K

Item 8.01

Other Events.

On May 30, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing new results from the AK112-206 trial (“AK112-206”), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer co-sponsored by the Company and its partner, Akeso, Inc. (“Akeso”), featuring ivonescimab. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

On May 31, 2026, the Company issued a press release noting that Akeso published results from the Phase III HARMONi-6 trial or AK112-306 (“HARMONi-6”). HARMONi-6 is a single region, multi-center Phase III study conducted in China sponsored by Akeso with all relevant data exclusively generated, managed, and analyzed by Akeso. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

The Company plans to utilize slides during its conference call scheduled for 7:00am ET on June 1, 2026, discussing the ivonescimab data from AK112-206 and HARMONi-6. A copy of the slides is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number

Description

99.1

Press Release, dated May 30, 2026

99.2

Press Release, dated May 31, 2026

99.3

Presentation Slides for June 1, 2026 Conference Call

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)